Ranjith Ramasamy, MD
Urology · Dubai, ZZNPI 1841459252
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Boston Scientific at 42.1% of the total. Reporting peaked in 2022 at $59,858 and has fallen 99.8% since, to $119 in 2025.
Across 379 payments — averaging $414.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$66K
- Coloplast$47K
- Acerus Pharmaceuticals Corporation$17K
- Aytu Biopharma, Inc.$12K
- Endo Pharmaceuticals Inc.$11K
- Antares Pharma, Inc.$3K
- plus $2K from 16 others
Across 18 payments — averaging $11,276 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acerus Pharmaceuticals Corporation$93K
- Endo Pharmaceuticals Inc.$57K
- Boston Scientific$44K
- Olympus America Inc.$9K
What the payments were for
- Consulting fees$49,30431%
- Speaking & faculty fees$63,88841%
- Travel & lodging$5,1303%
- Food & beverage$14,0589%
- Education$24,78016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 143 | $66,184 |
| Coloplast | 93 | $46,537 |
| Acerus Pharmaceuticals Corporation | 26 | $17,051 |
| Aytu Biopharma, Inc. | 9 | $11,905 |
| Endo Pharmaceuticals Inc. | 65 | $10,605 |
| Antares Pharma, Inc. | 8 | $3,340 |
| Vitrolife Inc. | 1 | $264 |
| Myriad Genetic Laboratories, Inc. | 4 | $239 |
| Olympus America Inc. | 4 | $207 |
| Johnson & Johnson | 10 | $181 |
| Axonics, Inc. | 1 | $141 |
| Greenwich Biosciences, Inc. | 1 | $107 |
| Intuitive Surgical | 1 | $71 |
| AbbVie | 2 | $64 |
| Clarus Therapeutics Inc. | 1 | $62 |
| Halozyme Inc | 2 | $46 |
| Rigicon,inc. | 2 | $42 |
| Pfizer | 2 | $40 |
| Tolmar, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $18 |
| Urovant Sciences Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$33,436
- Natesto$28,175
- GENERAL ERECTILE DYSFUNCTION$17,893
- TACTRA$12,000
- XIAFLEX$9,365
- AMS$7,415
- GENERAL - THERAPIES$4,803
- AMS 700 CXR RTE KIT$3,429
- TLANDO$3,110
- AdVance XP$1,721
- ADVANCE$1,125
- AMS 700$148
- Axonics$141
- NOCDURNA$110
- XYOSTED$110
- Epidiolex$107
- Dornier MedTech$107
How this compares
Too few urology providers in ZZto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Dubai
- Fernando SecinBuenos Aires$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.